JP2021535935A - ナノ乳化による製剤化カンナビス油粉末、その製造方法、及びその使用 - Google Patents

ナノ乳化による製剤化カンナビス油粉末、その製造方法、及びその使用 Download PDF

Info

Publication number
JP2021535935A
JP2021535935A JP2021547984A JP2021547984A JP2021535935A JP 2021535935 A JP2021535935 A JP 2021535935A JP 2021547984 A JP2021547984 A JP 2021547984A JP 2021547984 A JP2021547984 A JP 2021547984A JP 2021535935 A JP2021535935 A JP 2021535935A
Authority
JP
Japan
Prior art keywords
powder according
cannabinoid
powder
maltodextrin
pluronic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021547984A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021535935A5 (enExample
Inventor
マグダッシ，シュロモ
ラルシュ，リラズ
エズラ，ラファエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karnak Technologies LLC
Original Assignee
Karnak Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karnak Technologies LLC filed Critical Karnak Technologies LLC
Publication of JP2021535935A publication Critical patent/JP2021535935A/ja
Publication of JP2021535935A5 publication Critical patent/JP2021535935A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021547984A 2018-08-13 2019-03-11 ナノ乳化による製剤化カンナビス油粉末、その製造方法、及びその使用 Pending JP2021535935A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL261132A IL261132A (en) 2018-08-13 2018-08-13 Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
IL261132 2018-08-13
PCT/IL2019/050268 WO2020035850A1 (en) 2018-08-13 2019-03-11 Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof

Publications (2)

Publication Number Publication Date
JP2021535935A true JP2021535935A (ja) 2021-12-23
JP2021535935A5 JP2021535935A5 (enExample) 2022-01-25

Family

ID=63998426

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021547984A Pending JP2021535935A (ja) 2018-08-13 2019-03-11 ナノ乳化による製剤化カンナビス油粉末、その製造方法、及びその使用

Country Status (9)

Country Link
US (2) US11712430B2 (enExample)
EP (1) EP3716946A1 (enExample)
JP (1) JP2021535935A (enExample)
CN (1) CN113473965A (enExample)
AU (1) AU2019322212B2 (enExample)
BR (1) BR112021009869A2 (enExample)
CO (1) CO2021007647A2 (enExample)
IL (2) IL261132A (enExample)
WO (1) WO2020035850A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3138630A1 (en) * 2019-05-02 2020-11-05 Betterlife Pharma Inc. Cannabinoid stock transdermal formulations
US10780075B1 (en) 2019-07-31 2020-09-22 Etain IP, LLC Water soluble cannabis composition
AU2020330527A1 (en) * 2019-08-12 2022-02-24 Tenshi Kaizen Private Limited Cannabidiol orally disintegrating tablets
IL295386A (en) * 2020-07-29 2022-10-01 Karnak Tech Llc Improved formulations of lipophilic subtances for cosmetic uses
EP4057993A2 (en) 2020-07-29 2022-09-21 Karnak Technologies, LLC Oral compositions of lipophilic diety supplements, nutraceuticals and beneficial edible oils
AU2021317263B2 (en) * 2020-07-29 2024-08-01 Karnak Technologies, Llc Pharmaceutical compositions for improved delivery of therapeutic lipophilic actives
IL300499A (en) * 2020-08-14 2023-04-01 Capheads Llc Dosing capsule made from cannabis-derived resin and methods of making the same
CA3114085A1 (en) * 2021-04-05 2022-10-05 MEC11S Inc. Composition comprising cannabis extracts and method of manufacturing same
JP2023010676A (ja) * 2021-07-09 2023-01-20 株式会社東洋新薬 固形組成物
CN121752266A (zh) 2023-06-16 2026-03-27 湃珂知识产权有限责任公司 用于产生具有抗生素特性的大麻素皮米级乳剂的方法和所得的皮米级乳剂
US12605394B2 (en) 2024-07-25 2026-04-21 Visionary Assets, Llc Compositions containing cannabinoid nanoparticles
US12667578B2 (en) 2024-07-25 2026-06-30 Visionary Assets, Llc Cryogenic process for making cannabinoid nanoparticles and compositions made thereby
WO2026037496A1 (en) * 2024-08-14 2026-02-19 Tetra Pharm Technologies A self-emulsifying solid composition comprising a cannabinoid

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518097A (ja) * 2010-01-26 2013-05-20 イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー 肺高血圧を予防および治療するための組成物および方法
WO2017045053A1 (pt) * 2015-09-18 2017-03-23 Prati, Donaduzzi & Cia Ltda Composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso
JP2018516281A (ja) * 2015-05-28 2018-06-21 インシス・ディベロップメント・カンパニー・インコーポレイテッド 安定なカンナビノイド製剤
WO2018115962A1 (en) * 2016-12-20 2018-06-28 Tilray Inc. Novel cannabinoid compositions and methods of treating pediatric epilepsy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8629177B2 (en) * 2010-08-24 2014-01-14 Aphios Corporation Nanoencapsulated delta-9-tetrahydrocannabinol
ES2739194T3 (es) 2012-01-19 2020-01-29 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulación y método para aumentar la biodisponibilidad oral de fármacos
WO2013172999A1 (en) 2012-05-16 2013-11-21 Mewa Singh Pharmaceutical compositions for the delivery of substantially water-insoluble drugs
US10213391B2 (en) 2014-05-06 2019-02-26 Mewa Singh Pharmaceutical compositions comprising hemp and turmeric to treat pain and inflammation
US20160058866A1 (en) 2014-09-02 2016-03-03 Ronald D. Sekura Alternative solutions for the administration of cannabis derived botanical products
US9629886B2 (en) 2015-02-24 2017-04-25 Ers Holdings, Llc Method for conducing concentrated cannabis oil to be stable, emulsifiable and flavorless for use in hot beverages and resulting powderized cannabis oil
EP3270896A4 (en) 2015-03-19 2018-09-12 One World Cannabis Ltd. Preparations of cannabis emulsions and methods thereof
DK3368014T3 (da) * 2015-10-26 2024-01-08 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Nye formuleringer af cannabinoider
US20180206518A1 (en) 2016-04-15 2018-07-26 Ronald Silver Method of making cannabis oil hydrophilic using emulsifiers and related cannabinoid compositions
CO2017007962A1 (es) * 2017-08-04 2018-04-19 Alsec Alimentos Secos S A S Nanoparticulas oleosas de cannabis microencapsuladas en polvo

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518097A (ja) * 2010-01-26 2013-05-20 イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー 肺高血圧を予防および治療するための組成物および方法
JP2018516281A (ja) * 2015-05-28 2018-06-21 インシス・ディベロップメント・カンパニー・インコーポレイテッド 安定なカンナビノイド製剤
WO2017045053A1 (pt) * 2015-09-18 2017-03-23 Prati, Donaduzzi & Cia Ltda Composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso
WO2018115962A1 (en) * 2016-12-20 2018-06-28 Tilray Inc. Novel cannabinoid compositions and methods of treating pediatric epilepsy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DURAN-LOBATO, M., ET AL., JOURNAL OF NANOPARTICLE RESEARCH, vol. Vol.17, Issue 2, Article ID: 61, JPN6022045906, 2015, pages 1 - 17, ISSN: 0005193994 *
MARTIN-BANDERAS, L., ET AL., COLLOIDS AND SURFACES B: BIOINTERFACES, vol. 123, JPN6022045904, 2014, pages 114 - 122, ISSN: 0005193993 *

Also Published As

Publication number Publication date
BR112021009869A2 (pt) 2022-05-17
CN113473965A (zh) 2021-10-01
CA3086887A1 (en) 2020-02-20
WO2020035850A1 (en) 2020-02-20
US20210059975A1 (en) 2021-03-04
US11712430B2 (en) 2023-08-01
US20230321031A1 (en) 2023-10-12
EP3716946A1 (en) 2020-10-07
CO2021007647A2 (es) 2021-08-30
IL261132A (en) 2018-11-04
AU2019322212A1 (en) 2021-04-08
IL275430A (en) 2020-08-31
AU2019322212B2 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
US20230321031A1 (en) Formulated Cannabis Oil Powder By Nanoemulsifycation, Methods Of Producing And Uses Thereof
AU2017216928B2 (en) Oral solid cannabinoid formulations, methods for producing and using thereof
US11590230B2 (en) Compositions of therapeutic substances, methods and uses thereof
US20100119601A1 (en) Melatonin tablet and methods of preparation and use
CN112915121A (zh) 一种大麻素纳米胶束制剂及其制备方法
AU2021317263B2 (en) Pharmaceutical compositions for improved delivery of therapeutic lipophilic actives
WO2020146478A1 (en) Cannabinoid formulations for treating alcohol hangover
EP4405047B1 (en) Cannabinoid formulation for oral administration
US20180263954A1 (en) Sustained Release Cannabinoid Formulations
US20220193008A1 (en) Bioaccessibile compositions of lipophilic compounds and process thereof
KR20080007309A (ko) 신규의 활성 성분 전달용 갈렌계, 제조 방법 및 용도
Javed et al. Patented bioavailability enhancement techniques of silymarin
CA3086887C (en) Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
CA3005885A1 (en) Sustained release cannabinoid pellets
HK40053715A (en) Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220117

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230925

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231013

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231117